Wordt geladen...
Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, importa...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Hindawi Limited
2016-01-01
|
| Reeks: | Journal of Diabetes Research |
| Online toegang: | http://dx.doi.org/10.1155/2016/8352957 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|